179 related articles for article (PubMed ID: 12202284)
1. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
Emsley R; Myburgh C; Oosthuizen P; van Rensburg SJ
Am J Psychiatry; 2002 Sep; 159(9):1596-8. PubMed ID: 12202284
[TBL] [Abstract][Full Text] [Related]
2. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
[TBL] [Abstract][Full Text] [Related]
3. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
4. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
5. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
6. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
7. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
[TBL] [Abstract][Full Text] [Related]
8. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
[TBL] [Abstract][Full Text] [Related]
10. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
11. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial.
Mozaffari-Khosravi H; Yassini-Ardakani M; Karamati M; Shariati-Bafghi SE
Eur Neuropsychopharmacol; 2013 Jul; 23(7):636-44. PubMed ID: 22910528
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
[TBL] [Abstract][Full Text] [Related]
14. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ
Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.
Frangou S; Lewis M; McCrone P
Br J Psychiatry; 2006 Jan; 188():46-50. PubMed ID: 16388069
[TBL] [Abstract][Full Text] [Related]
16. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
17. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
Goff DC; Keefe R; Citrome L; Davy K; Krystal JH; Large C; Thompson TR; Volavka J; Webster EL
J Clin Psychopharmacol; 2007 Dec; 27(6):582-9. PubMed ID: 18004124
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T
Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
